Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) — Corporate Action | 1 October 2026

Jagsonpal Pharmaceuticals announced the completion of its acquisition of the Wellness Portfolio from Group Pharmaceuticals Limited effective October 1, 2026, following regulatory approvals and satisfaction of all conditions precedent under the Business Transfer Agreement signed on September 23, 2026. The transaction adds a complementary consumer wellness platform with established regional presence across six states and approximately 30,000 doctors, strengthening Jagsonpal's Rx portfolio and distribution network. The company emphasized this acquisition aligns with its ₹500 Cr revenue ambition and strategic inorganic growth model, preserving liquidity through a deferred payment structure while maintaining over ₹100 crores in cash reserves. The filing includes investor presentation materials detailing synergies, financial impact, and integration plans.